Healthcare Resource Utilization (HCRU) in Treatment of Patients with Localized/Locally Advanced Prostate Cancer (LPC/LAPC) in a Portuguese Comprehensive Cancer Center (PCCC)
Author(s)
Braga I1, Monteiro S2, Calisto R3, Rangel M4, Medeiros E4, Cunha JL2, Rosinha A1, Oliveira A5, Bento MJ4, Santos S6, Lopes R7, Redondo P4
1Urology Clinic, Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Centre (Porto.CCC) & RISE@CI-IPOP (Health Research Network), Porto, Portugal, Porto, Portugal, 2IPO Porto, Porto, 13, Portugal, 3Department of Epidemiology,Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Centre (Porto.CCC) & RISE@CI-IPOP (Health Research Network), Porto, Portugal, Porto, Portugal, 4IPO Porto, Porto, Portugal, 5Radiation Oncology Department, Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Centre (Porto.CCC) & RISE@CI-IPOP (Health Research Network), Porto, Portugal, Porto, Portugal, 6Janssen Portugal, Lisboa, Portugal, 7Janssen Portugal, Lisboa, 15, Portugal
Presentation Documents
OBJECTIVES: Despite the high prevalence of LPC/LAPC, evidence regarding the treatment of these conditions is scarce. This study assessed HCRU in the treatment of LPC/LAPC in a PCCC.
METHODS: A retrospective observational cohort analysis was conducted using a PCCC database. This study included patients with LPC/LAPC diagnosed between January 2015 - December 2017 and followed until December 2020.
Patients were classified as LPC or LAPC according to European Association of Urology Guidelines and considered eligible if diagnosed in stage I to III and followed in the Outpatient Clinic service of: Urology, Medical Oncology or Radiation Oncology. Data was collected from medical/administrative records.s. HCRU outcomes included: outpatient and emergency room (ER) visits; hospitalizations; complementary diagnostic and therapeutic procedures (CDTs).RESULTS: A total of 2194 patients were identified and 790 were considered eligible (677 LPC and 113 LAPC patients) and observed over a median follow-up of 47 months. Risk stratification was conducted on LPC patients, showing that 36% No statistical differences were found between groups concerning clinical and demographic characteristics. Hospitalizations were mostly due to radical prostatectomy and brachytherapy, which accounted for 35% and 30% of hospitalizations (n=533).
Hospitalization occurred in 27% of LAPC versus 58% of LPC patients, with non-high-risk LPC showing a higher hospitalization rate than high-risk LPC (69% vs 38%). The average length of stay was comparable between cohorts: 4.37, 3.56 and 4.39 days, respectively. High-risk LPC showed higher outpatient HRU compared to non-high-risk LPC, as average outpatient and ER visits per patient increased by 12% and 47%, while average number of CDTs per patient increased by 40%. LAPC outpatient HRU was comparable to high-risk LPC.CONCLUSIONS: Treatment of early prostate cancer requires significant HRU, particularly for high-risk LPC and LAPC. Given the high prevalence of these conditions, the treatment is likely to result in a high budget impact for hospitals.
Conference/Value in Health Info
Value in Health, Volume 25, Issue 12S (December 2022)
Code
HSD35
Topic
Clinical Outcomes, Economic Evaluation, Real World Data & Information Systems
Topic Subcategory
Clinical Outcomes Assessment, Health & Insurance Records Systems
Disease
SDC: Oncology